Serum Levels of sRAGE, the Soluble Form of Receptor for Advanced Glycation End Products, Are Associated with Inflammatory Markers in Patients with Type 2 Diabetes
Molecular Medicine volume 13, pages 185–189 (2007)
Advanced glycation end products (AGEs) and their receptor (RAGE) play an important role in accelerated atherosclerosis in diabetes. We have recently found that the soluble form of RAGE (sRAGE) levels are significantly higher in type 2 diabetic patients than in nondiabetic subjects and positively associated with the presence of coronary artery disease in diabetes. In this study, we examined whether serum levels of sRAGE correlated with inflammatory biomarkers in patients with type 2 diabetes. Eighty-six Japanese type 2 diabetic patients (36 men and 50 women, mean age 68.4 ± 9.6 years) underwent a complete history and physical examination, determination of blood chemistries, sRAGE, monocyte chemotactic protein-1 (MCP-1), adiponectin, tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6). Univariate regression analysis showed that serum levels of sRAGE positively correlated with alanine aminotransferase (ALT) (r = 0.437, P = 0.0001), MCP-1 (r = 0.359, P = 0.001), TNF-α (r = 0.291, P = 0.006), and hyperlipidemia medication (r = 0.218, P = 0.044). After multiple regression analyses, ALT (P < 0.0001), MCP-1 (P = 0.007), and TNF-α (P= 0.023) remained significant. The present study demonstrates for the first time that serum levels of sRAGE are positively associated with MCP-1 and TNF-α levels in type 2 diabetic patients. These observations suggest the possibility that sRAGE level may become a novel biomarker of vascular inflammation in type 2 diabetic patients.
Reducing sugars can react nonenzymatically with amino groups of protein to form Amadori products. These early glycation products undergo further complex reactions such as rearrangement, dehydration, and condensation to become irreversibly cross-linked, heterogeneous fluorescent derivatives, termed advanced glycation end products (AGEs) (1–4). There is a growing body of evidence that AGEs and their receptor (RAGE) are implicated in the pathogenesis of diabetic vascular complications (5–8). Indeed, engagement of RAGE with AGEs is shown to elicit oxidative stress generation and subsequently evoke inflammatory responses in endothelial cells (ECs). Moreover, administration of a recombinant soluble form of RAGE (sRAGE) consisting of the extracellular ligand-binding domain has been shown not only to suppress the development of atherosclerosis but also to stabilize established atherosclerosis in diabetic apolipoprotein Enull mice (9,10). These observations suggest that exogenously administered sRAGE may capture and eliminate circulating AGEs, thus protecting against AGE-induced tissue damage and dysfunction by acting as a decoy. However, little is known about the regulation and role of endogenous sRAGE in patients with diabetes.
We have recently found that sRAGE levels are significantly higher in type 2 diabetic patients than in nondiabetic subjects and positively associated with the presence of coronary artery disease in diabetes (11). These findings suggest that endogenous sRAGE level may be elevated in diabetes as a counter-system against EC damage and could reflect enhanced RAGE expression in the diabetic vasculature. In this study, we examined whether serum levels of sRAGE correlated with inflammatory biomarkers in patients with type 2 diabetes.
The study involved consecutive outpatients with type 2 diabetes in Nakamura Clinic (68.4 ±9.6 y old, 36 men and 50 women, 22 with diabetic nephropathy, 19 with diabetic retinopathy) with a mean (± SD) duration of diabetes of 9.0 ± 7.1 years and a current hemoglobin A1c (HbA1c) of 7.6% ± 1.4%. The diagnosis of type 2 diabetes was determined by the criteria of the American Diabetes Association reported in 1997 (12). We excluded patients with active inflammatory disease, acute coronary syndromes, and cancers.
Medical history and use of tobacco and alcohol were ascertained by a questionnaire. Smoking and alcohol were classified as current habitual use or not. Height and weight were measured, and BMI (kilograms per meter squared) was calculated as an index of presence or absence of obesity. Blood pressure was measured in the sitting position (first) and supine position (second) at 3-min intervals using an upright standard sphygmomanometer. Vigorous physical activity and smoking were avoided for at least 30 min before blood pressure measurement. The second blood pressure measurement with the fifth-phase diastolic pressure was used for analysis.
Blood was drawn from the antecubital vein for determining lipids (total cholesterol, HDL cholesterol, LDL cholesterol, and triglycerides), plasma glucose, HbA1c, creatinine, uric acid, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and γ-glutamyl transpeptidase (GTP). The chemistries were measured at a commercial laboratory (Wakamatsu Medical Research Laboratory, Kitakyushu, Japan). Serum levels of sRAGE, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and adiponectin were determined with commercially available ELISA kits (R&D Systems, Minneapolis, MN, USA). These samples were processed blindly. ELISA assay was run in duplicate. All participants gave informed consent.
Mean values with upper and lower 95% CIs were exponentiated and presented as geometric mean ± SD, where the SD was approximated as the difference of the exponentiated CI divided by 3.92, which is the number of SD in a 95% CI where data are normally distributed. Results are presented as mean ± SD. The medications for hypertension, hyperlipidemia, and diabetes were coded as dummy variables. Univariate analysis was performed for determinants of serum sRAGE levels. To determine independent determinants of sRAGE levels, multiple linear regression analysis was performed. Statistical significance was defined as P < 0.05. All statistical analyses were performed with the use of the SPSS system.
Clinical characteristics of the patients are presented in Table 1. As shown in Table 1, 65 patients received antihypertensive agents (17 angiotensin-converting enzyme inhibitors, 22 angiotensin II type 1 receptor blockers). The mean serum levels of sRAGE in this population was 601.8 ± 477.3 pg/mL (range 188.4–3964.4 pg/mL). Figure 1 and Table 2 show results of univariate and multivariate analyses for determinants of serum sRAGE levels. Parameters statistically and significantly related to sRAGE levels were ALT (r = 0.437, P = 0.0001), MCP-1 (r = 0.359, P = 0.001), TNF-α (r = 0.291, P = 0.006), and hyperlipidemia medication (r = 0.218, P = 0.044). Because these significant parameters could be closely correlated with each other, multiple linear regression analysis was performed. Finally, ALT (P < 0.0001), MCP-1 (P = 0.007), and TNF-α (P = 0.023) still remained significant and were independently related to serum levels of sRAGE (R2 = 0.309).
In this study, we demonstrated for the first time that serum levels of sRAGE were associated with some inflammatory markers such as MCP-1 and TNF-α in patients with type 2 diabetes. Our study suggests the possibility that circulating endogenous sRAGE levels may become a novel biomarker of vascular inflammation in type 2 diabetic patients.
The concept that circulating endogenous sRAGE may reflect tissue RAGE expression is supported by the following observations: (a) RAGE belongs to the same immunoglobulin superfamily as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), and serum levels of soluble forms of ICAM-1 and VCAM-1 are elevated in patients with diabetes, reflecting upregulation of these adhesion molecules in endothelial cells (ECs) (13–15). (b) Angiotensin II increases RAGE mRNA levels in ECs and subsequently stimulates sRAGE formation. Treatment with telmisartan, an angiotensin II type 1 receptor blocker, not only inhibits the angiotensin II-elicited sRAGE generation by ECs, but also decreases serum levels of sRAGE in patients with essential hypertension (16). (c) AGEs are positive regulators of cell expression of RAGE, and serum sRAGE levels are positively, rather than inversely, associated with circulating AGE levels in humans (17). (d) Vitreous levels of sRAGE are increased in proliferative retinal diseases, reflecting enhanced RAGE expression in epiretinal membranes of the eyes (18). (e) Several reports show that RAGE is upregulated in atherosclerotic plaques in diabetes (19), diabetic nephropathy (20), and retinopathy (18). These observations suggest that circulating endogenous sRAGE could reflect tissue RAGE expression and may increase as a counter-system against EC injury in diabetic patients.
A growing body of evidence suggests that RAGE is a signal transducing receptor for AGEs and that engagement of RAGE elicits vascular inflammation, thus being involved in accelerated atherosclerosis in diabetes (5–7). Moreover, RAGE expression in the vasculature is enhanced in diabetes (19), and sRAGE could be generated from the cleavage of cell surface RAGE in ECs (16,21,22). In addition, we have recently found that sRAGE levels are significantly higher in type 2 diabetic patients than in nondiabetic control subjects and positively associated with the presence of coronary artery disease in diabetes (11). These findings further support the concept that circulating sRAGE levels may reflect tissue RAGE expression and become a novel biomarker of vascular damage in type 2 diabetic patients.
We and others have shown that RAGE mediates the AGE-signaling to MCP-1 and TNF-α expression in various types of cells including ECs (23–26). Further, several reports show the positive correlation between serum levels of MCP-1 and TNF-α and circulating AGE levels (27,28). These observations suggest that enhancement of the AGE-RAGE axis under diabetic conditions could partly account for the positive association between endogenous sRAGE levels and these inflammatory markers in our patients.
In this study, serum sRAGE levels showed the strongest association with ALT. The correlation with ALT was stronger than that of MCP-1 and TNF-α and remained so even after multiple linear regression (Table 2). Among various liver enzymes, ALT is most closely related to liver fat accumulation, and consequently ALT has been used as a marker of nonalcoholic fatty liver in diabetes (29). We have recently found that serum AGE levels are significantly elevated in patients with nonalcoholic steatohepatitis compared with simple steatosis or healthy control subjects, and that the AGE-RAGE interaction induces transforming growth factor-β in human cultured hepatic stellate cells (HSCs), promoting the transdifferentiation of HSCs to myofibroblasts and thereby being involved in the process of liver fibrosis (unpublished data). These observations suggest that circulating sRAGE could reflect liver RAGE expression as well and may be elevated in response to nonalcoholic liver injury, thus being positively associated with ALT levels in our subjects.
Although serum levels of sRAGE can be influenced by agents that block the renin-angiotensin system or by renal function (16,30,31), it is unlikely that they could confound the present results because univariate analysis revealed no significant correlation between the medication for hypertension or serum creatinine levels and serum sRAGE levels in our subjects (Table 2). Further, in the present study, sRAGE levels were not associated with serum creatinine levels, a finding inconsistent with the result of Tan et al. (30). The difference of subject population (mean serum creatinine levels in our cases were 0.89 mg/dL, whereas those in Tan et al. were 1.05 mg/dL) and ethnicity could account for the discrepancy. Therefore, the lack of association between sRAGE and creatinine does not necessarily suggest a selection bias in our cases. In addition, in this study, serum sRAGE levels were associated with hyperlipidemia medication in univariate, but not multivariate, analyses. Strong correlation between sRAGE levels and inflammatory biomarkers such as MCP-1 and TNF-α in hyperlipidemic patients who received hyperlipidemia medication may account for the result.
Basta et al. (32) recently reported that plasma sRAGE (measured by the same commercial ELISA kit as this study) was inversely associated with the inflammatory marker C-reactive protein (CRP), which was also independently associated with sRAGE on stepwise regression analysis in their subjects (diabetic patients and controls). However, they also reported that CRP was not identified as an independent predictor of plasma sRAGE in diabetic patients when analyses were performed separately in the two groups. Therefore, our data showing the positive association between sRAGE and some inflammatory markers are not necessarily discrepant with their findings. The finding that sRAGE was inversely, rather than positively, associated with HbA1c in their subjects appears to be in contrast to our previous observation that serum sRAGE levels are positively associated with circulating AGE levels in nondiabetic subjects (17) because HbA1c is one of the early glycation products. The different turnover rate in AGEs and HbA1c or the difference of ethnic background between subjects may account for the discrepant results.
A couple of other papers have reported circulating RAGE levels in diabetic patients (33,34), but all of them measured C-truncated splice isoform of secretory RAGE levels, but not total endogenous sRAGE levels (35). Katakami et al. (33) reported in Japanese that the serum levels of C-truncated RAGE were significantly decreased in patients with type 1 diabetes compared with nondiabetic subjects (266 ± 89 vs. 436 ± 121 pg/mL, P < 0.0001). They also reported that BMI and HbA1c were inversely correlated with C-truncated RAGE levels, being independent risk factors for low C-truncated RAGE values. Decreased C-truncated RAGE levels have also been found to be one of the independent risk factors for carotid atherosclerosis (34). Koyama et al. (34) reported that serum C-truncated RAGE levels were decreased in Japanese type 2 diabetic patients compared with nondiabetic subjects (176 ± 92 vs. 253 ± 111 pg/mL, P < 0.01) and the low levels were associated with the components of the metabolic syndrome and carotid atherosclerosis. These observations were contrary to our findings that total endogenous sRAGE levels are associated with conventional coronary risk factors including inflammatory markers and one of the independent determinants of coronary artery disease in diabetes (11). Endogenous sRAGE may generate from cleavage of cell-surface RAGE or novel splice variants of RAGE (16,21,22, 35). We measured total endogenous sRAGE levels, while Koyama et al. (34) only detected some splice variant-derived C-truncated RAGE; C-truncated RAGE levels in Koyama et al. were approximately three- to four-fold lower than total sRAGE levels in our study. Therefore, the kinetics of total and some splice variant-derived C-truncated RAGE could differ in diabetic subjects. Decreased levels of the splice variant-derived C-truncated RAGE may be associated with comorbidity such as diabetes, metabolic syndrome, and atherosclerosis by unknown mechanisms (other than working as a decoy), because our recent findings suggest that total endogenous sRAGE levels are not sufficient to efficiently eliminate circulating AGEs in humans (17).
First, our study was cross-sectional and therefore does not elucidate the causal relationships between serum sRAGE levels and some inflammatory markers such as MCP-1 and TNF-α. Therefore, we do not know whether total sRAGE levels could be mechanistically related to vascular inflammation by reflecting tissue RAGE expression. Eventually, a longitudinal study is needed to clarify the causal relationship between sRAGE levels and vascular inflammatory markers in type 2 diabetes. Second, the aim of this study was to elucidate the regulation and role of total endogenous sRAGE in type 2 diabetic patients. We focused on diabetic patients because we have recently found that sRAGE levels are significantly higher in type 2 diabetic patients than in nondiabetic control subjects and positively associated with the presence of coronary artery disease in diabetes (11). Therefore, we do not know the relationship between sRAGE and inflammatory markers in nondiabetic control subjects. From the present study, whether sRAGE is the most convenient biomarker for evaluating vascular inflammation in diabetic patients is not known. Further study is needed to clarify whether evaluation of total sRAGE levels offers any advantages over more standard assays of inflammation.
Vlassara H, Bucala R, Striker L. (1994) Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Invest. 70:138–50.
Brownlee M. (1995) Advanced protein glycosylation in diabetes and aging. Ann. Rev. Med. 46:223–34.
Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. (1991) Formation of pentosidine during nonenzymatic browning of proteins by glucose. J. Biol. Chem. 18:11654–60.
Grandhee S, Monnier VM. (1991) Mechanism of formation of the Maillard protein cross-link pentosidine. J. Biol. Chem. 18:11649–53.
Schmidt AM, Stern D. (2000) Atherosclerosis and diabetes: the RAGE connection. Curr Atheroscler Rep. 5:430–6.
Schmidt AM, Yan SD, Wautier JL, Stern D. (1999) Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84:489–97.
Yamagishi S, Imaizumi T. (2005) Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr. Pharm. Des. 11:2279–99.
Ueda S et al. (2006) Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol. Med. 180:180–4.
Park L et al. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products. Nat. Med. 4:1025–31.
Bucciarelli L et al. (2002) RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106:2827–35.
Nakamura K et al. (2006) Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease. Diabetes Metab. Res. Rev. 10.1002/dmrr.690
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:183–97.
Ferri C, Desideri G, Baldoncini R, Bellini C, De Angelis C, Mazzocchi C, Santucci A. (1998) Early activation of vascular endothelium in nonobese, nondiabetic essential hypertensive patients with multiple metabolic abnormalities. Diabetes 47:660–7.
Rosei EA, Rizzoni D, Muiesan ML, Sleiman I, Salvetti M, Monteduro C, Porteri E, CENTRO (CandEsartaN on aTherosclerotic Risk factors) study investigators. (2005) Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J. Hypertens. 23:435–44.
Steiner M, Reinhardt KM, Krammer B, Ernst B, Blann AD. (1994) Increased levels of soluble adhesion molecules in type 2 (non-insulin dependent) diabetes mellitus are independent of glycaemic control. Thromb. Haemost. 72:979–84.
Nakamura K et al. (2005) Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. Microvasc. Res. 70:137–41.
Yamagishi S et al. (2006) Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55:1227–31.
Pachydaki SI et al. (2006) Upregulation of RAGE and its ligands in proliferative retinal disease. Exp. Eye Res. 82:807–15.
Cipollone F et al. (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108:1070–7.
Tanji N et al. (2000) Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J. Am. Soc. Nephrol. 11:1656–66.
Schlueter C, Hanke S, Flohr AM, Rogalla P, Bullerdiek J. (2003) Tissue specific expression patterns of RAGE receptor and its soluble forms: a result of regulated alternative splicing? Biochem. Biophys. Acta 1630:1–6.
Hudson BI, Harja E, Moser B, Schmidt AM. (2005) Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein? Arterioscler. Thromb. Vasc. Biol. 25:879–82.
Gu L et al. (2006) Role of receptor for advanced glycation end-products and signaling events in advanced glycation end-product-induced monocyte chemoattractant protein-1 expression in differentiated mouse podocytes. Nephrol. Dial. Transplant. 21:299–313.
Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. (2003) Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 46:284–7.
Rashid G, Benchetrit S, Fishman D, Bernheim J. (2004) Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells. Kidney Int. 66:1099–106.
Cataldegirmen G et al. (2005) RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J. Exp. Med. 201:473–84.
Galli F, Benedetti S, Floridi A, Canestrari F, Piroddi M, Buoncristiani E, Buoncristiani U. (2005) Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int. 67:750–9.
Hein GE, Kohler M, Oelzner P, Stein G, Franke S. (2005) The advanced glycation end product pentosidine correlates to IL-6 and other relevant inflammatory markers in rheumatoid arthritis. Rheumatol. Int. 26:137–41.
Schindhelm RK et al. (2006) Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab. Res. Rev. 22:437–43.
Tan et al. (2006) Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes. Diabetologia 49:2756–62.
Geroldi D, Falcone C, Emanuele E. (2006) Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13:1971–8.
Basta G et al. (2006) Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab. 91:4628–34.
Katakami N et al. (2005) Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28:2716–21.
Koyama H et al. (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25:2587–93.
Yonekura H et al. (2003) Novel splice variants of the receptor for advanced glycation endproducts expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370:1097–109.
This study was supported in part by Grants of Collaboration with Venture Companies Project from the Ministry of Education, Culture, Sports, Science and Technology, Japan (S.Y.).
About this article
Cite this article
Nakamura, K., Yamagishi, Si., Adachi, H. et al. Serum Levels of sRAGE, the Soluble Form of Receptor for Advanced Glycation End Products, Are Associated with Inflammatory Markers in Patients with Type 2 Diabetes. Mol Med 13, 185–189 (2007). https://doi.org/10.2119/2006-00090.Nakamura
- sRAGE Levels
- Hyperlipidemia Medications
- Nondiabetic Control Subjects
- Diabetic Patients
- Vascular Inflammation